Table 2 Baseline differences between patients who did or did not achieve drug-free remission after 4 years
Drug-free remission N  =  67No drug-free remission N  =  441p Value
Age, years56 (15)54 (14)0.45
Men, n (%)35 (52)130 (29)<0.001*
Time from diagnosis to inclusion, weeks (median, IQR)2 (1–4)2 (1–5)0.63
Symptom duration, weeks (median, IQR)18 (11–33)24 (14–56)0.007*
IgM rheumatoid factor negative, n (%)32 (48)147 (33)0.02
Anti-CCP negative, n (%)38 (57)144 (36)0.001*
DAS4.1 (0.8)4.5 (0.9)0.004
HAQ, 0–3 scale1.2 (0.6)1.4 (0.7)0.002
VAS pain (mm)45 (22)55 (22)0.001
VAS disease activity (mm)55 (19)61 (23)0.04
VAS morning stiffness (mm)54 (24)60 (24)0.04
Erosive, n (%)44 (69)313 (72)0.60
Total SHS, 0–448 scale (median, IQR)3.3 (1.0–6.9)4.0 (1.5–9.0)0.18
  • *Independently associated with drug-free remission after 4 years. Values are the mean (SD) unless indicated otherwise. CCP, citrullinated peptide; DAS, disease activity score (44 joints); HAQ, health assessment questionnaire; IQR, interquartile range; SHS, modified Sharp/van der Heijde Score; VAS, visual analogue scale.